Oppenheimer analyst Jay Olson reiterated an Outperform rating and $140.00 price target on Nektar Therapeutics (NASDAQ: NKTR).The analyst commented: "This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments